Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study.
10.3904/kjim.2005.20.3.237
- Author:
Ock Bae KO
1
;
Shin KIM
;
Hyeok SHIM
;
Jung Hun LEE
;
Jung Min AHN
;
Soon Man YOON
;
Min Hyok JEON
;
Il No DO
;
So Young LEE
;
Yong Gil KIM
;
Sang We KIM
;
Sung Bae KIM
;
Sang Hee KIM
;
Jung Shin LEE
;
Wookun KIM
;
Chan Jung PARK
;
Hyun Sook CHI
;
Cheolwon SUH
Author Information
1. Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. csuh@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Multiple myeloma;
Autologous;
Stem cell transplantation
- MeSH:
Vincristine/administration & dosage;
Transplantation, Autologous;
*Stem Cell Transplantation;
Retrospective Studies;
Recombinant Proteins/administration & dosage;
Multiple Myeloma/drug therapy/*therapy;
Middle Aged;
Male;
Korea;
Humans;
Granulocyte Colony-Stimulating Factor/administration & dosage;
Female;
Doxorubicin/administration & dosage;
Dexamethasone/administration & dosage;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage;
Antineoplastic Agents/*therapeutic use;
Aged;
Adult
- From:The Korean Journal of Internal Medicine
2005;20(3):237-242
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Although high dose chemotherapy coupled with an autologous stem cell transplantation (ASCT) is widely accepted as effective therapy for multiple myeloma (MM), few reports are available in Korea, especially in the area of double ASCT. We present the results of an institutional retrospective study of 12 patients with MM treated by double ASCT. METHODS: Eligible patients received induction therapy using vincristine, adriamycin, dexamethasone (VAD), and mobilization was performed using cyclophosphamide plus lenograstim. High-dose melphalan (total 200 mg/m2) was used to condition the ASCT. RESULTS: The median interval from diagnosis to ASCT was 6 months (range, 1.8-15.3 months). The median interval between the 1st and 2nd ASCT was 4.4 months (range 2.1-48.7 months). The median follow up was 18.3 months (range 8.1-50.5 months) for the nine surviving patients. No therapy-related mortality occurred. Following induction chemotherapy, two patients experienced CR. Following double ASCT, eight patients experienced CR. The 5 year OS was 59%. The median duration of event free survival was 2.13 years (95% CI, 0.84-3.42). CONCLUSION: Although the results of study did not demonstrate the advantage of double ASCT, this is the first report to outline the outcome of double ASCT for Korean MM patients.
